Hint mode is switched on Switch off
For swift navigation between sections

Neurogene

PDF download

Choose all Reset all
Download Cancel
Organization name
Neurogene, Inc
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Neurogene is a biopharmaceutical company creating next generation immunotherapies using de novo protein design technology. Neurogeneuses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.

Awards

News

12/05/2026 Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
24/03/2026 Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
24/03/2026 Neurogene: And Exhibit, Financial Statements And Exhibits
12/01/2026 Neurogene: And Exhibits 99.1 Amd 99.2 Attached Hereto Are Being Furnishedand Shall Not Be Deemed “filed” For The Purposes Of Section18 Of The Securities Exchange Act Of 1934, As Amended (the "exchange Act"), Or Otherwise Subject To The Liabilities Of That Section, Nor Shall Such Information Or Exhibit 99.1 Or 99.2 Be Deemed Incorporated By Reference Into Any Filing Under The Exchange Act Or The Securities Act Of 1933, As Amended, Except As Expressly Set Forth By Specific Reference To Such Filing, Financial Statements And Exhibits
13/11/2025 Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001404644
  • EIN
    98-0542593
Registration is required to get access.